SHERIDAN, WYOMING – July 25, 2025 – Maryland continues to assert itself as a national leader in life sciences, driven by a dynamic workforce, strong academic institutions, and expanding industry infrastructure. With the Washington, D.C.–Baltimore area ranking among the top six U.S. regions for R&D and manufacturing talent, the state is attracting significant investment and fostering sustainable growth across biotech and pharmaceutical sectors.

Talent-Driven Advantage for Life Sciences Expansion

According to a recent CBRE report, the Washington, D.C.–Baltimore metro ranks third in the nation for life sciences R&D talent and sixth for manufacturing. This robust talent ecosystem, combined with Maryland’s strategic geographic positioning, makes it a compelling destination for biotech and pharmaceutical companies.

SHERIDAN, WYOMING – July 25, 2025 – Roche has officially discontinued development of CT-173, an investigational PYY analog once positioned as a novel obesity treatment, citing a lack of competitiveness and development potential in its latest strategic assessment.

The decision, announced during the company’s second-quarter earnings call, marks a clear pivot in Roche’s prioritization within its obesity drug pipeline, following its high-profile acquisition of Carmot Therapeutics for $2.7 billion in December 2023. The move reflects Roche’s sharpened focus on only the most promising assets as the obesity drug market becomes increasingly competitive.

Early-stage candidate fails to meet internal thresholds

SHERIDAN, WYOMING – July 25, 2025 – Roche has reported strong momentum in the first half of 2025, achieving 7% sales growth at constant exchange rates (CER) and a 23% increase in IFRS net income, driven by high demand for innovative pharmaceutical treatments and effective cost control measures.

Strong Performance in Pharmaceuticals Drives Growth

Roche’s Pharmaceuticals Division delivered a standout performance, with sales rising 10% (CER) to CHF 24.0 billion. This increase was propelled by robust demand for key therapies including Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus, which together contributed CHF 10.6 billion in sales — a CHF 1.7 billion increase over the same period last year.

SHERIDAN, WYOMING – July 25, 2025 – Roche has received CE Mark certification for its Elecsys® pTau181 blood test, marking a pivotal advancement in Alzheimer’s diagnostics by introducing the first IVDR-certified in-vitro diagnostic test to help rule out Alzheimer’s-associated amyloid pathology. Developed in collaboration with Eli Lilly and Company, the test is designed to help clinicians exclude Alzheimer’s disease as the cause of cognitive decline using a simple blood sample, significantly reducing the need for invasive confirmatory procedures like PET scans or CSF analysis.

Minimally Invasive Test Aims to Address Diagnostic Gaps

SHERIDAN, WYOMING – July 25, 2025 – Roche has received European Commission (EC) approval for Itovebi™ (inavolisib), a targeted therapy for adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer. The approval marks a significant milestone in the treatment of a subtype associated with poor prognosis and limited therapeutic options.

Regulatory milestone based on robust clinical evidence

The EC’s decision was driven by data from the pivotal phase III INAVO120 study, published in The New England Journal of Medicine in October 2024. The trial demonstrated that the Itovebi-based regimen—when used in combination with palbociclib (Ibrance®) and fulvestrant—more than doubled progression-free survival (15.0 months vs. 7.3 months; HR=0.43; p<0.001) compared with palbociclib and fulvestrant alone.

SHERIDAN, WYOMING – July 25, 2025 – Roche has announced a significant step in the modernization of its capital structure, as its Board of Directors proposes to exchange the company's non-voting equity securities ("Genussscheine") for newly issued participation certificates. The proposal, which will be submitted to shareholders for approval at the 2026 Annual General Meeting (AGM), aims to align Roche’s capital instruments with current Swiss corporate law and modern market practices.

The proposed participation certificates will carry a nominal value of CHF 0.001 each and be listed on the SIX Swiss Exchange, offering the same economic value and entitlements as the Genussscheine they replace. In tandem, Roche also plans to reduce the nominal value of its bearer shares from CHF 1.00 to CHF 0.001 per share. This will result in a cash repayment of CHF 0.999 per bearer share, totaling approximately CHF 106.6 million, contingent on shareholder approval.

SHERIDAN, WYOMING – July 25, 2025 – Roche has announced topline results from two pivotal clinical trials evaluating astegolimab for chronic obstructive pulmonary disease (COPD), highlighting a complex development path for the investigational monoclonal antibody. The phase IIb ALIENTO trial met its primary endpoint, while the phase III ARNASA trial did not, despite both showing numerical reductions in exacerbation rates.

Phase IIb ALIENTO Achieves Statistically Significant Reduction in Exacerbations

The ALIENTO study, which enrolled 1,301 patients, demonstrated a statistically significant 15.4% reduction in the annualised exacerbation rate (AER) over 52 weeks when astegolimab was administered every two weeks on top of standard COPD maintenance therapy. The patient population included both current and former smokers, regardless of blood eosinophil count, with a history of frequent exacerbations.

SHERIDAN, WYOMING – July 25, 2025 – Küppersbusch Hausgeräte GmbH will present a fully redesigned dishwasher product line during Küchenmeile 2025, marking a significant milestone in the company’s strategic product development roadmap. Hosted in the brand’s showroom at Gut Böckel, this major industry event underscores Küppersbusch’s ongoing commitment to design excellence, energy efficiency, and market-driven innovation.

Showcasing Innovation and Strategic Expansion

Under the guiding theme “Inspire 2025: Impulse. Innovation. Interaktion.”, Küppersbusch invites trade partners, planners, and kitchen specialists to engage directly with its brand environment and explore key innovations that will shape the upcoming kitchen season. The introduction of an entirely new dishwasher portfolio marks a pivotal moment in the company's expansion efforts.

SHERIDAN, WYOMING – July 25, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has reaffirmed its long-term strategic transformation during its virtual Annual General Meeting (AGM) for fiscal year 2024/2025, underscoring the company’s commitment to becoming a systems integrator in packaging and to expanding into new technology-driven markets.

With approximately 27.5 percent of HEIDELBERG's share capital represented, the Management Board presented a comprehensive overview of the company’s financial performance, strategic progress, and outlook through a live-streamed session for shareholders and stakeholder representatives.

Positioning HEIDELBERG for the Future

SHERIDAN, WYOMING – July 25, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has signed an agreement with the Polar Group to acquire the technology, brand rights, and intellectual property (IP) of the renowned postpress specialist Polar Mohr, marking a pivotal step in its expansion strategy for the packaging and label market. The acquisition will give HEIDELBERG exclusive global rights for sales, service, and marketing of Polar Mohr postpress products, further solidifying its position as a comprehensive systems integrator.

Strategic Growth through Consolidation